Clinical Study

A Randomized, Placebo Controlled Phase 2B/3 Study Of Abt-414 With Concurrent Chemoradiation And Adjuvant Temozolomide In Subjects With Newly Diagnosed

Posted Date: May 15, 2019

  • Investigator: Rekha Chaudhary
  • Specialties:
  • Type of Study: Drug

The main purposes of this study are to evaluate whether combining ABT-414 with usual RT and TMZ treatment controls GBM better than usual RT and TMZ without ABT-414, and whether ABT-414 makes patients live longer. This study will only include people whose tumors are tested and confirmed to have EGFR

Criteria:

To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Glioblastoma (Brain Tumor).

Keywords:

M13-813, Glioblastoma, Brain, Egfr1, Cancer

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.